# Awiqli Flextouch (insulin icodec) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/insulin-icodec

> The FDA approved Awiqli Flextouch (insulin icodec), sponsored by NOVO NORDISK A S (NVO), on March 26, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Awiqli Flextouch (insulin icodec) |
| Codes |  |
| Sponsor | NOVO NORDISK A S (NVO) https://sec-api.dev/companies/nvo/catalysts |
| Indications | [Diabetes Mellitus, Type 1](https://sec-api.dev/indications/diabetes-mellitus-type-1), [Diabetes, Type 2](https://sec-api.dev/indications/diabetes-type-2) |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### July 10, 2024: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed the review of BLA 761326/Original 1 and BLA 761326/Original 2, as amended, and have determined that we cannot approve these applications in their present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761326_20240710.pdf%22

### May 8, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Diabetes, Type 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06340854 (A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Novo Nordisk A/S; Results First Posted 2026-07-02." https://clinicaltrials.gov/study/NCT06340854

### March 26, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761326 ORIG-2 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20260326, review_priority STANDARD; sponsor_name NOVO NORDISK INC; product AWIQLI FLEXTOUCH (INSULIN ICODEC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761326%22

### July 2, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Diabetes, Type 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06340854 (A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Novo Nordisk A/S; Results First Posted 2026-07-02." https://clinicaltrials.gov/study/NCT06340854?tab=results

### October 23, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761326 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20261023, review_priority PRIORITY; sponsor_name NOVO NORDISK INC; product AWIQLI FLEXTOUCH (INSULIN ICODEC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761326%22

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Diabetes Mellitus, Type 1.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07076199 (A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07076199

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Diabetes Mellitus, Type 1.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07076199 (A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07076199

## Same indication

- [OLUMIANT® (baricitinib)](https://sec-api.dev/pdufa/baricitinib) (LLY)
- [Cadisegliatin](https://sec-api.dev/pdufa/cadisegliatin) (VTVT)
- [Dasiglucagon](https://sec-api.dev/pdufa/dasiglucagon) (NVO)
- [Zimislecel](https://sec-api.dev/pdufa/zimislecel) (VRTX)

Calendar months: [January 2027](https://sec-api.dev/fda-calendar/2027-01)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/insulin-icodec.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Awiqli Flextouch (insulin icodec) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/insulin-icodec

```bibtex
@misc{secapidev_pdufa_insulin_icodec_20261116,
  title        = {Awiqli Flextouch (insulin icodec) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/insulin-icodec}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_insulin_icodec_20261116","title":"Awiqli Flextouch (insulin icodec) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/insulin-icodec","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
